DLPIC
ALXN

Davide Leone & Partners Investment Company’s Alexion Pharmaceuticals ALXN Stock Holding History

Davide Leone & Partners Investment Company’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-14,236
Closed -$2.18M – 126
2021
Q1 		$2.18M Hold
14,236
– – 0.27% 44
2020
Q4 		$2.22M Buy
+14,236
New +$1.83M 0.23% 21

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Davide Leone & Partners Investment Company's ALXN Position: Q2 2021 in Review

Davide Leone & Partners Investment Company sold out of Alexion Pharmaceuticals (ALXN) in Q2 2021, closing a stake of 14,236 shares — an estimated $2.18M sold.

Davide Leone & Partners Investment Company first reported a position in ALXN in Q4 2020 and held it in 2 quarters. The position peaked at $2.22M in Q4 2020. 708 funds tracked by Wall St. Rank hold ALXN as of Q2 2021.

  • Davide Leone & Partners Investment Company reported no remaining Alexion Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Davide Leone & Partners Investment Company sold 14,236 Alexion Pharmaceuticals shares in Q2 2021, an estimated $2.18M.
  • Davide Leone & Partners Investment Company first reported a position in Alexion Pharmaceuticals in Q4 2020 and held it in 2 quarters.
  • Davide Leone & Partners Investment Company's Alexion Pharmaceuticals position peaked at $2.22M in Q4 2020.
  • 708 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2021.

Based on Davide Leone & Partners Investment Company's 13F filing for Q2 2021, filed 16 Aug 2021.